Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
62
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
April 30, 2007
Conditions
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerLarge Cell Lung CancerMalignant Pleural EffusionRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG
docetaxel
Given IV
BIOLOGICAL
cetuximab
Given IV
DRUG
bortezomib
Given IV
Trial Locations (1)
33140
Mount Sinai Comprehensive Cancer Center, Miami Beach
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00118183 - Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter